Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 23, 2025, reports a significant regulatory milestone for its oncology portfolio. The announcement concerns the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issuing a positive opinion for Blenrep (belantamab mafodotin) in combination therapies for relapsed or refractory multiple myeloma.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory update focused on clinical trial outcomes and approval status rather than a financial results report.
Material Changes and Clinical Outcomes
The primary material change is the positive CHMP opinion supporting the approval of Blenrep combinations in Europe, following prior approvals in the UK (April 2025) and Japan. This opinion is based on superior efficacy demonstrated in two Phase III trials:
- DREAMM-7: Compared Blenrep + bortezomib + dexamethasone (BVd) against daratumumab + bortezomib + dexamethasone (DVd).
- Progression-Free Survival (PFS): Median PFS was 36.6 months for BVd versus 13.4 months for DVd (HR 0.41).
- Overall Survival (OS): Showed a 42% reduction in the risk of death (HR 0.58). The three-year OS rate was 74% for BVd versus 60% for DVd.
- DREAMM-8: Compared Blenrep + pomalidomide + dexamethasone (BPd) against bortezomib + pomalidomide + dexamethasone (PVd) in patients previously treated with lenalidomide.
- PFS: Median PFS was not yet reached for BPd versus 12.7 months for PVd (HR 0.52). At one year, 71% of BPd patients were alive and progression-free versus 51% for PVd.
- OS: A positive trend was observed (HR 0.77) but was not statistically significant at the interim analysis.
Guidance, Outlook, and Risks
Outlook and Approval Timeline:
- Europe: A final approval decision by the European Commission is expected in Q3 2025.
- United States: The FDA Prescription Drug User Fee Act (PDUFA) decision date is set for July 23, 2025.
- China: The application has received Breakthrough Therapy Designation and priority review.
- Other Markets: Priority review is ongoing in Canada and Switzerland.
Management Commentary: GSK management highlights that Blenrep is the only anti-BCMA antibody-drug conjugate (ADC) for multiple myeloma, offering a differentiated mechanism of action suitable for administration in community settings without complex pre-administration regimens.
Risks and Safety:
- Adverse Events: Common non-ocular adverse events include thrombocytopenia (87% in DREAMM-7, 55% in DREAMM-8), neutropenia (63% in DREAMM-8), and diarrhea (32% in DREAMM-7).
- Ocular Toxicity: Eye-related side effects are manageable and reversible with dose modifications, with discontinuation rates due to these effects at or below 9% in both trials.
- Forward-Looking Statements: GSK cautions that actual results may differ from projections due to risks outlined in their 2024 Form 20-F and Q1 2025 results.
Investor Verification Checklist
- Confirm the final European Commission approval decision in Q3 2025.
- Monitor the FDA PDUFA decision on July 23, 2025, for US market access.
- Verify the commercial launch strategy and pricing for Blenrep combinations in Europe following approval.
- Review the final Overall Survival (OS) data from the DREAMM-8 trial, as the interim analysis was not statistically significant.
- Assess the competitive landscape for anti-BCMA therapies in the relapsed/refractory multiple myeloma space.